Program
Iron
Also written as “PA21”, “PA21 (2.5 g tablet containing 500 mg iron)” and “CTX001 With Iron”.
Its studies are mostly in Hyperphosphatemia · Anemia · Renal Insufficiency, Chronic · Colorectal Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 100 open or running | phase 3since Mar 24, 2011 | Jan 9, 2009 | none ahead |
| Kissei Pharmaceutical | 50 open or running | phase 3since Apr 12, 2013 | Jan 26, 2012 | none ahead |
| Cajal Therapeutics | 11 open or running | early phase 1since May 5, 2026 | May 5, 2026 | none ahead |
| J. Uriach | 10 open or running | phase 4since Sep 16, 2005 | Sep 16, 2005 | none ahead |
Also a collaborator on its studies: Fresenius Medical Care.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 16, 2005First study: phase 4 study in Colorectal NeoplasmsNew to J. UriachJ. Uriach · NCT00199277 · 150 enrolled · Spain
- Jan 9, 2009CSL's first study: phase 2 study in Renal Insufficiency, ChronicNew to CSLCSL · NCT00824460 · 154 enrolled · United States, Bulgaria, Croatia and more
- Mar 24, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisCSL · NCT01324128 · 1,059 enrolled · United States, Austria, Belgium and more
- Mar 25, 2011Phase 1 study in Drug Interaction PotentiationCSL · NCT01324752 · 36 enrolled · United States
- Sep 12, 2011Phase 3 study in Chronic Kidney Disease Requiring Chronic DialysisCSL · NCT01464190 · 659 enrolled · United States, Austria, Belgium and more
- Sep 16, 20112 phase 1 studies in HealthyCSL · NCT01438359, NCT01452906
- Nov 16, 20112 phase 1 studies in Drug Interaction PotentiationCSL · NCT01477424, NCT01477411
- Jan 26, 2012Kissei Pharmaceutical's first study: phase 2 study in HyperphosphatemiaNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT01521494 · 183 enrolled · Japan
- Apr 12, 2013Phase 3 study in HyperphosphatemiaKissei Pharmaceutical · NCT01833494 · 161 enrolled · Japan
- May 7, 20133 phase 3 studies in HyperphosphatemiaKissei Pharmaceutical · NCT01852682, NCT01850641, NCT01850602
- Jul 5, 2017No phase study in AnemiaCSL · NCT03214627 · 88 enrolled · United Kingdom
- Aug 21, 2018Phase 3 study in HyperphosphatemiaCSL · NCT03644264 · 286 enrolled · China
- May 5, 2026Cajal Therapeutics's first study: early phase 1 study in AnemiaNew to Cajal TherapeuticsCajal Therapeutics · NCT07577817 · 72 planned · Australia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07577817Anemia · Australia | Early 1 | Recruiting | Cajal Therapeutics | Oct 2026 | 72 |
| NCT03644264Hyperphosphatemia · China | 3 | Completed | CSL | Aug 21, 2020 | 286 |
| NCT03214627Anemia · United Kingdom | – | Terminated | CSL | May 21, 2019 | 88 |
| NCT01852682Hyperphosphatemia · Japan | 3 | Completed | Kissei Pharmaceutical | Mar 2014 | |
| NCT01850641Hyperphosphatemia · Japan | 3 | Completed | Kissei Pharmaceutical | Dec 2013 | 35 |
| NCT01850602Hyperphosphatemia · Japan | 3 | Completed | Kissei Pharmaceutical | Dec 2013 | 213 |
| NCT01833494Hyperphosphatemia · Japan | 3 | Completed | Kissei Pharmaceutical | Aug 2014 | 161 |
| NCT01521494Hyperphosphatemia · Japan | 2 | Completed | Kissei Pharmaceutical | Jul 3, 2012 | 183 |
| NCT01477424Drug Interaction Potentiation · United States | 1 | Completed | CSL | Feb 2012 | 45 |
| NCT01477411Drug Interaction Potentiation · United States | 1 | Completed | CSL | Jan 2012 | 42 |
| NCT01452906Healthy · United States | 1 | Completed | CSL | Dec 2011 | 45 |
| NCT01438359Healthy · United States | 1 | Completed | CSL | Sep 2011 | 42 |
| NCT01464190Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more | 3 | Completed | CSL | Oct 2012 | 659 |
| NCT01324752Drug Interaction Potentiation · United States | 1 | Completed | CSL | Jun 2011 | 36 |
| NCT01324128Chronic Kidney Disease Requiring Chronic Dialysis · United States, Austria, Belgium and more | 3 | Completed | CSL | Apr 2012 | 1,059 |
| NCT00824460Renal Insufficiency, Chronic · United States, Bulgaria, Croatia and more | 2 | Completed | CSL | Oct 2009 | 154 |
| NCT00199277Colorectal Neoplasms · Spain | 4 | UNKNOWN | J. Uriach | 150 |
How it is read
Names in the registry
- “PA21”, 11 entries
- “PA21 (2.5 g tablet containing 500 mg iron)”, 2 entries
- “CTX001 With Iron”, 1 entry
- “IV iron”, 1 entry
- “1.25 g PA21 (250 mg iron)”, 1 entry
Codes read as this program: PA21.
Conditions, from the studies’ own filings
- Hyperphosphatemia, 6 studies
- Anemia, 2 studies
- Renal Insufficiency, Chronic, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.